The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
Elena Rangelova(Sahlgrenska University Hospital), Emanuele F. Kauffmann(University of Pisa), Carmen Payá‐Llorente(Hospital Universitario Doctor Peset), Daisuke Douchi(Tohoku University), Allard G Wijma(University Medical Center Groningen), Claudio Ricci(Azienda USL di Bologna), C. Månsson(Uppsala University), Elizabeth Pando(Universitat Autònoma de Barcelona), Alessandro Giani(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Bradley N. Reames(Nebraska Medical Center), Tess M. E. van Ramshorst(Fondazione Poliambulanza Istituto Ospedaliero), Atsushi Oba(Tokyo Medical and Dental University), Ali Arshad(Southampton General Hospital), Mahsoem Ali(Amsterdam Neuroscience), Apurva Jain(University of Oklahoma Health Sciences Center), Els Moltzer(Radboud University Nijmegen), Charles de Ponthaud(Sorbonne Université), Carlos Domingo del Pozo(Hospital Universitario Doctor Peset), Andrea Coratti(Ospedale Misericordia - Grosseto), Bobby Tingstedt(Lund University), Alejandro Serrablo, Alessandro Giardino(Casa di Cura Villa Garda), E. Steyerberg(Leiden University Medical Center), A. Banerjee(The Royal Free Hospital), Daisuke Hashimoto(Kansai Medical University), Thomas F. Stoop(Amsterdam University of Applied Sciences), Cornelius A. Thiels(Mayo Clinic in Arizona), Brian K. P. Goh(Singapore General Hospital), Bergþór Björnsson(Linköping University), Donzília Sousa Silva(Hospital de Santo António), David Kilburn(Flinders Medical Centre), Christoph Schwabl(Innsbruck Medical University), Alain Sauvanet(Hôpital Beaujon), Andreas Socratous(Sahlgrenska University Hospital), Aslam Ejaz(University of Illinois Chicago), Alessandro Zerbi(Humanitas University), C. González-Abós(Hospital Clínic de Barcelona), Dyre Kleive(Oslo University Hospital), Barish H. Edil(Johns Hopkins University), Andrea Zironda(Mayo Clinic), Ammar A. Javed(NYU Langone Health), Chie Takishita(Tokyo Medical University), Eduard A. van Bodegraven(Emma Kinderziekenhuis), Aram Rojas(Endeavor Health), B.Y. Patel(Southampton General Hospital), D L Hughes(Oxford University Hospitals NHS Trust), C. Medin(Emory University), A. Halimi(Karolinska University Hospital), D Flanking(Sahlgrenska University Hospital), Casper H.J. van Eijck(Erasmus MC)
Cited by 11
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
|Science|2011|1.7k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k